A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

To be considered for this study, you must be a male aged 18 or older with a confirmed diagnosis of prostate cancer that has spread and is resistant to hormone therapy. Your cancer must be a specific type called adenocarcinoma. You would also need to be generally well, able to perform daily activities with ease, and have certain blood test results and a specific level of PSA (a protein in the blood linked to prostate cancer).

There are also reasons why you might not be able to join. For example, if you have certain other serious medical conditions like specific brain issues, or if you've recently had other cancer treatments that caused severe side effects that haven't cleared up. You also can't be allergic to any ingredients in the study medicines. The team will carefully check all your medical information to see if this study is suitable for you.

Information about what taking part in this study involves isn't fully detailed in the summary provided. However, typically in a study like this (Phase 1), you would likely have regular visits to the hospital or clinic. During these visits, you would receive the study medication (JNJ-78278343 and JNJ-95298177), undergo various tests to check your health, such as blood tests, scans, and physical examinations. These tests help the doctors monitor how your body is responding to the treatment and check for any side effects. You would also have follow-up appointments after the main treatment phase to continue monitoring your health. The total duration of your participation would be explained in full by the study team, but Phase 1 studies often involve intensive monitoring over several months.